Status:
TERMINATED
Study Evaluating Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Neoplasms
Eligibility:
All Genders
20-74 years
Phase:
PHASE1
Brief Summary
The primary purpose of this study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of CMD-193 administered intravenously (IV) to subjects with advanced malignant tumors. The s...
Eligibility Criteria
Inclusion
- Malignant solid tumor progressed, or no standard treatment available
- Tumor expression of Lewis Y antigen
Exclusion
- Cancer therapy within 28 days before enrollment
- Pregnant or breastfeeding women
- Unstable or serious concurrent medical conditions
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT00257881
Start Date
November 1 2005
End Date
December 1 2006
Last Update
December 10 2007
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Tokyo, Chuo-ku, Japan, 104-0045
2
Nagaizumi-cho, Sunto-gun, Shizuoka, Japan, 411-8777